Radioligand Therapy
•13 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (13)
| Company | Market Cap | Price |
|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
The RM2/LNTH-2401/2503 theranostic assets represent radioligand therapy opportunities, a distinct investable theme in radiopharmaceuticals.
|
$4.69B |
$68.60
-0.55%
|
|
IMNM
Immunome, Inc.
IMNM includes radioligand therapy assets such as IM-3050 (FAP-targeted RLT).
|
$1.72B |
$19.39
-1.60%
|
|
BCYC
Bicycle Therapeutics plc
BRCs fall under radioligand therapy, a distinct radiopharmaceutical approach.
|
$458.12M |
$6.54
-1.06%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
SADA PRIT includes radioligand therapy concepts (radioligand-based targeting).
|
$389.89M |
$8.61
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101-Lu and related alpha-emitter radioconjugates constitute radioligand therapy, a subset of radiopharmaceuticals.
|
$380.87M |
$56.59
-8.33%
|
|
CATX
Perspective Therapeutics, Inc.
Core focus on radioligand therapy using alpha emitters (Lead-212) to target tumors.
|
$202.74M |
$2.83
+3.85%
|
|
MOLN
Molecular Partners AG
Lead radioligand therapy program MP0712 demonstrates DLL3 targeting with radioligand delivery.
|
$139.79M |
$4.31
+2.34%
|
|
PSTV
Plus Therapeutics, Inc.
Therapeutic modality: radioligand therapy targeting CNS tumors.
|
$55.68M |
$0.56
+0.34%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Core platform involves radioligand-like delivery of radioactive payloads to tumors via targeting molecules (ARC/antibody-based radiotherapy).
|
$45.23M |
$1.44
-0.69%
|
|
RADX
Radiopharm Theranostics Limited
Theranostic radiopharmaceuticals using radiolabeled ligands for targeted cancer therapy.
|
$33.67M |
$4.80
-5.88%
|
|
RDGL
Vivos Inc.
Radioligand Therapy is a related investable cancer therapy modality that RDGL's RadioGel exemplifies.
|
$31.33M |
$0.07
|
|
CLRB
Cellectar Biosciences, Inc.
Direct radioligand therapy modality using radioactive isotopes conjugated to targeting platforms, a key therapy approach described.
|
$10.69M |
$3.17
-5.37%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
PSMA-targeted radioligand therapy represents a radioligand therapy approach within their theranostic program.
|
$1.98M |
$1.79
-2.97%
|
Loading company comparison...
Loading industry trends...
Loading research report...
